Safety and Efficacy Results of Phase I/II SCOOP Trial in mCRC

April 2, 2018
Akihito Kawazoe, MD

Akihito Kawazoe, MD, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin plus pembrolizumab for treatment of patients with metastatic colorectal cancer.

Akihito Kawazoe, MD, lead investigator in the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin (BBI608) plus pembrolizumab (Keytruda) for treatment of patients with metastatic colorectal cancer (mCRC).

Kawazoe presented these results at the 2018 Gastrointestinal Cancers Symposium. This multicenter study sought to discover the right dose level for napabucasin and to identify the efficacy of this treatment combination.

It was found that the combination of napabucasin plus pembrolizumab was very tolerable with little adverse events. Researchers also found which treatment dose was the most effective. According to the results of this study, patients can most benefit from a napabucasin dose of 480 mg per day.

Read more onthis treatment combination for metastatic colorectal cancer.